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warfarin.	The	mean	CHA2DS2-VASc	 score	was	2.5	 (±1.6).	 In	patients	without	pre-
vious	 anticoagulation	 treatment,	 NOACs	 were	 associated	 with	 a	 shorter	 mean	
time	to	cardioversion	than	warfarin	(51	versus.	68	days,	respectively;	p	<	.001).	Six	
thromboembolic	events	 (0.6%)	occurred:	4	 (0.7%)	 in	NOAC-treated	patients	and	2	






had a shorter time to cardioversion and continued their anticoagulation therapy more 
often than patients on warfarin.
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associated with an increased risk for thromboembolic events such as 
ischemic stroke and systemic embolism. Without preceding antico-
agulation,	there	is	a	5%–7%	risk	of	thromboembolism	(Arnold,	Mick,	
Mazurek,	Loop,	&	Trohman,	1992),	and	with	adequate	anticoagula-
tion	 therapy,	 the	 risk	 is	 reduced	 to	0.5%–1.6%	 (Klein	et	al.,	2001).	
According	to	the	current	AF	guidelines,	adequate	oral	anticoagula-
tion is recommended for at least 3 weeks before and for a minimum 
of	4	weeks	after	ECV	in	patients	with	AF	>	48	hr	or	of	unknown	du-
ration,	regardless	of	their	stroke	risk	profiles	(Kirchhof	et	al.,	2016).




ate	 NOAC	 treatment	 (Forslund,	 Wettermark,	 &	 Hjemdahl,	 2016;	
Huisman	et	al.,	2015).	Due	to	their	rapid	onset	of	action,	their	pre-
dictable pharmacokinetics and pharmacodynamics and their ability 
to	 be	 used	 at	 fixed	 doses	 without	 routine	 laboratory	 monitoring,	




which	may	prolong	 the	 time	until	 ECV	can	be	performed	 (Ryman,	









sons	 for	 the	 changes	between	NOACs	 and	VKAs	 and	 for	 the	dis-
continuation of anticoagulation is essential to ensure treatment 
adherence	and	to	minimize	the	risk	of	potential	bleeding	and	throm-
boembolic events.
The aim of this study was to investigate the reasons for the de-
lays	in	ECV,	the	frequency	of	switching	anticoagulants,	and	the	rates	







to whether or not they had or did not have ongoing anticoagulation 
therapy	at	the	time	of	AF	diagnosis.	Data	on	the	patient	characteris-
tics,	delays	to	cardioversion,	success	of	cardioversion,	anticoagula-
tion	 treatment,	acute	 (<30	days)	 complications	 (stroke	or	 systemic	





tom history in the patient's chart to the time of cardioversion. 
Delayed cardioversion was defined as postponed or canceled pri-
mary	ECV,	as	documented	in	the	medical	records	by	a	physician	or	
a nurse. Cardioversion was considered successful if sinus rhythm 
was restored and maintained for at least five minutes. The primary 
endpoint measure was stroke or systemic embolism. Patients were 
classified as having an embolic event if a thromboembolism was con-
firmed	by	computerized	tomography	or	magnetic	resonance	imaging	
or documented clinically by a physician. The primary safety outcome 
was any bleeding event reported in the patient's medical record 
during	a	30-day	follow-up.	Major	bleeding	events	were	defined	ac-
cording to the International Society of Thrombosis and Haemostasis 
criteria	(Schulman	&	Kearon,	2005).	Switches	between	NOACs	and	
VKAs	and	discontinuations	of	NOAC	therapy	were	analyzed	during	
a 12-month postcardioversion period.
2.1 | Statistical analysis
Continuous variables were tested for normality of distribution with 
the	Kolmogorov–Smirnov	test.	Normally	distributed	data	were	ana-
lyzed	 using	 Student's	 t	 test	 and	 presented	 as	 the	mean	 (standard	
deviation [SD]).	 Skewed	 continuous	 data	were	 analyzed	 using	 the	
Mann–Whitney	U	 test	 and	 presented	 as	 the	median	 (interquartile	








mean	 age,	 68.0	 ±	 10.0).	 The	 patient	 characteristics	 of	 the	NOAC	
and	 warfarin	 groups	 are	 shown	 in	 Table	 1.	 The	 mean	 CHA2DS2-
VASc	 score	was	2.5	 (range	0–8),	 and	72.3%	of	 the	patients	had	 a	
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revealed one intraventricular thrombus in a patient receiving dabi-




















The	 majority	 of	 cardioversions	 were	 successful	 (89.7%	 in	 the	
NOAC	 group	 and	 89.1%	 in	 the	warfarin	 group;	 p	 =	 .75).	 The	 suc-
cess	rate	was	94.3%	for	cardioversions	with	AF	duration	<	1	week,	
93.0%	for	cardioversions	with	AF	durations	of	1	week	to	1	month,	





During	 the	 30-day	 follow-up	 period	 after	 ECV,	 thromboembolic	
complications	occurred	 in	 four	patients	 (0.7%)	 in	 the	NOAC	group	
and	two	patients	(0.5%)	in	the	warfarin	group	(p	=	.25).	All	patients	





farin	and	3	patients	 (0.5%)	receiving	NOACs	 (p	=	 .27).	The	patient	
characteristics of those with thromboembolic and bleeding compli-
cations are shown in Table 3.
3.4 | Anticoagulation after cardioversion
Among	 900	 patients,	 99	 patients	 (11.0%)	 experienced	 treatment	
changes	 during	 a	 12-month	 postcardioversion	 period:	 82	 patients	
switched	 from	 warfarin	 to	 NOAC,	 seven	 patients	 switched	 from	
NOAC	 to	warfarin,	 and	 three	 patients	 switched	between	NOACs.	
The	reasons	for	the	changes	between	OACs	are	shown	in	Table	4.	
One	hundred	fifty-seven	patients	 (17.4%)	stopped	their	anticoagu-
lation	 therapy	 four	weeks	after	ECV	because	of	 a	CHA2DS2-VASc	
score less than 2.
4  | DISCUSSION
The	results	of	this	real-life	study	showed	that	NOACs	were	associ-




The	 real-life	 data	 evaluating	 the	 safety	 and	 efficacy	 of	 ECV	
in	patients	receiving	NOACs	are	sparse	 (Frederiksen	et	al.,	2018;	
Pallisgaard	 et	 al.,	 2015).	 In	 line	 with	 previous	 studies	 (Cappato	
et	 al.,	 2014;	 Goette	 et	 al.,	 2016),	 the	 precardioversion	 use	 of	
NOACs	enabled	faster	progression	to	ECV	with	fewer	cancelations	
TA B L E  1   Patient characteristics
Patients characteristics
NOAC
N = 596 
(60.0%)
Warfarin




Age	(mean	±	SD) 67.1	(±10.2) 68.9	(±9.5) .004
CHA2DS2-VASc	score 2.2	(±1.5) 2.7	(±1.6) <.001
HAS-BLED	score 0.8	(±0.7) 1.1	(±0.8) <.001
Congestive heart failure 61	(11.3) 50	(14.0) .27
Hypertension 315	(58.1) 257	(71.8) <.001
Diabetes mellitusa  97	(17.9) 76	(21.2) .52
History	of	stroke	or	TIA 13	(2.4) 24	(6.7) .29
Liver	cirrhosisb  0	(0.0) 2	(0.6) .08
Renal failurec  13	(2.4) 26	(7.3) <.001




Bleeding	tendencye  4	(0.7) 8	(2.0) .59
Known	thrombophilia 7	(1.3) 7	(2.0) .36
Antiarrhythmic	therapyf 	
precardioversion
61	(10.2) 36	(9.1)  
Antiarrhythmic	therapy	
postcardioversion








significant bleeding event. 
fClasses	I-IV	according	to	Vaughan	Williams	classification	plus	digoxin.	
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of	planned	ECVs	than	warfarin.	The	median	time	to	the	index	ECV	
was	37	days,	which	was	shorter	than	that	of	patients	treated	with	
warfarin	 in	previous	 studies	 (Lehto	&	Kala,	 2003).	 The	 tendency	
toward a shorter time to cardioversion in real-life patients was 
also	noted	in	two	Danish	studies,	where	in	one	study,	the	waiting	
time	for	cardioversion	in	the	NOAC	group	was	28	days,	and	in	the	
other	study,	80%	of	 the	cardioversions	 in	 the	NOAC	group	were	
performed	 within	 28	 days	 (Frederiksen	 et	 al.,	 2018;	 Pallisgaard	
et	al.,	2015).	In	our	study,	the	median	time	to	index	ECV	for	NOAC-
treated	patients	was	higher	than	the	median	times	of	those	studies,	







dioversion also in patients having warfarin and should therefore be 
used more often in our system.
There are limited data on the reasons for the delay to cardio-
version.	 In	 this	 study,	 patients	 receiving	warfarin	had	 significantly	
more	 frequent	 delays	 to	 ECV	 than	patients	 receiving	NOACs.	 For	
warfarin-treated	patients,	the	main	reasons	for	ECV	postponements	
were	labile	INR	values.	A	major	disadvantage	of	warfarin	is	its	nar-
row	 therapeutic	window,	 causing	 easily	 subtherapeutic	 INR	 levels	
and	delays	in	ECV.	Earlier	reports	(Itainen	et	al.,	2018;	Lehto	&	Kala,	
2003)	have	suggested	that	a	shorter	duration	from	the	onset	of	AF	










In	 line	 with	 previous	 studies	 (Lehto	 &	 Kala,	 2003;	 Ruff	
et	 al.,	 2014),	 the	 incidence	 of	 thromboembolic	 and	 bleeding	 com-
plications	in	real-life	patients	undergoing	ECV	was	low	in	the	pres-
ent study. Thromboembolic complications occurred in two patients 
(0.5%)	in	the	warfarin	group	and	four	patients	(0.7%)	in	the	NOAC	
F I G U R E  1   Duration of anticoagulation 
before elective cardioversion in patients 
without	preexisting	anticoagulation	
therapy.	The	vertical	line	through	the	box	


























Delay 75	(12.6) 148	(37.4) <.001
Labile	INR	values	
(warfarin)
0	(0.0) 121	(81.8)  
Noncompliance	
(NOAC)




5	(6.7) 1	(0.7)  
Infection 5	(6.7) 1	(0.7)  
Heart failure 9	(12.0) 13	(8.9)  
Hyper- or 
hypothyroidism
3	(4.0) 2	(1.4)  
Travel 10	(13.3) 0	(0.0)  
Surgery 4	(5.3) 0	(0.0)  
Hypokalemia 1	(1.3) 1	(0.7)  
Referral problems 8	(10.7) 2	(1.4)  
Othera  10	(13.3) 4	(2.7)  
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group.	The	CHA2DS2-VASc	score	was	higher	in	the	warfarin	group	
than	in	the	NOAC	group,	but	the	number	of	thromboembolic	events	
was so low that possible differences between the warfarin and 
NOAC	groups	could	not	be	determined.	No	major	or	fatal	bleeding	
events were documented during the follow-up.
In	 11.0%	 of	 the	 patients,	 the	 anticoagulation	 treatment	 was	
changed	during	the	one-year	 follow-up	after	 the	 index	ECV.	The	
rate	for	switches	between	OACs	was	 lower	than	those	of	earlier	
studies	 (Beyer-Westendorf	et	al.,	2015;	Hellfritzsch	et	al.,	2017),	





had	 a	 higher	 drug	 persistence	 rate	 within	 one	 year	 after	 ECV	
than patients who were prescribed warfarin. Thromboembolic or 




cohort as precisely as a prospective trial. We were dependent on 
the data recorded by the physicians who performed the cardiover-
sions	and	who	were	responsible	for	follow-up.	Moreover,	the	clini-




the onset of arrhythmia was based on the beginning of the patient's 
symptoms	 in	 the	medical	 records,	making	the	exact	onset	difficult	
to	determine.	Also,	echocardiography	was	not	performed	 in	every	
patient in the real-life setting and we could not collect comprehen-
sive	data	on,	for	example,	 left	atrial	size	which	might	affect	AF	re-







TA B L E  3   Characteristics of the patients with thromboembolic or bleeding complications





1 Stroke 4 64 Female 1 0 Rivaroxaban	20	mgx1
2 Stroke 2 88 Female 3 1 Warfarin
3 TIA 9 75 Female 3 1 Warfarin
4 TIA 14 61 Male 2 0 Apixaban	5	mgx2
5 TIA 21 78 Male 3 2 Rivaroxaban	15	mgx1
6 Central retinal vein 
thrombosis
24 79 Male 3 1 Rivaroxaban	20	mgx1
1 GI-bleeding 30 80 Female 3 2 Warfarin
2 GI-bleeding 14 60 Male 1 0 Warfarin
3 GI-bleeding 28 74 Female 5 2 Warfarin
4 GI-bleeding 13 78 Female 3 2 Warfarin
5 GI-bleeding 6 68 Male 7 3 Warfarin
6 GI-bleeding 2 86 Male 5 2 Rivaroxaban	15	mgx1
7 Nosebleed 18 72 Male 1 1 Rivaroxaban	15	mgx1
8 Postmenopausal 
bleeding
12 79 Female 3 1 Dabigatran	150	mgx2
9 Bleeding	unspecified 30 84 Male 4 2 Warfarin
10 Bleeding	unspecified 24 71 Male 4 3 Warfarin
Abbreviations:	GI,	gastrointestinal;	TIA,	transient	ischemic	attack.
TA B L E  4  Reason	for	change	in	99	patients	(11.0%)	who	changed	
their anticoagulation treatment during the study
Reason No. (%)
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5  | CONCLUSION
The	use	of	NOACs	seems	to	be	as	safe	and	effective	as	that	of	war-
farin in the real-world setting of elective cardioversion. Patients 
receiving warfarin have significantly more delays in treatment than 
patients	receiving	NOACs,	prolonging	the	time	to	ECV.	Furthermore,	
our	results	indicate	better	adherence	with	NOACs	than	with	warfa-
rin in the daily care of patients.
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